prevalent vertebral fracture

Related by string. * Prevalent . PREVALENT : prevalent lysosomal storage . prevalent sexually transmitted . More Prevalent . Prevalent Networks / Vertebral : vertebral compression fractures VCFs . vertebral augmentation . osteoporotic vertebral compression fractures / Fractures . Fracture . FRACTURE : multiple skull fractures . depressed skull fracture . sustained hairline fracture * *

Related by context. Frequent words. (Click for all words.) 60 vertebral fracture 57 thromboembolic events 56 FOLFIRI 56 P = .# 56 confidence interval #.#-#.# 54 noninferiority 54 % CI #.#-#.# [006] 54 IPSS 53 evaluable 53 neoadjuvant chemotherapy 53 composite endpoint 53 dacarbazine 53 annualized relapse 53 pg mL 52 venous thrombosis 52 myocardial infarctions 52 unfractionated heparin 52 peginterferon alfa 2b 52 undetectable viral load 52 prognostic factor 52 Recurrence Score 52 52 PCa 52 nonsignificant 52 venous thromboembolism 52 distant metastases 52 osteoporotic 52 hepatocellular carcinoma HCC 52 zoledronic acid 51 median PFS 51 placebo p = 51 decitabine 51 femoral neck 51 peginterferon alfa 2a 51 metastatic renal cell carcinoma 51 creatinine clearance 51 LVEF 51 serum phosphorus 51 teriparatide 51 neoplasm 51 thromboembolism 51 alendronate 51 placebo p 51 ECOG 51 adenoma 51 nondiabetic 51 CYPHER ® Stent 51 adjuvant chemotherapy 51 ziprasidone 51 HbA1c levels 51 vertebral fractures 50 FOLFOX 50 TAXUS stent 50 insulin glargine 50 risedronate 50 mg BID 50 CaP 50 CD4 + cell 50 VTE 50 evaluable patients 50 ± SD 50 adalimumab 50 ticagrelor 50 microalbuminuria 50 DAS# [002] 49 azathioprine 49 epoetin alfa 49 BRCA2 mutations 49 HER2 negative 49 serum concentrations 49 Median survival 49 statistically significant p 49 cells/mm3 49 premenopausal 49 chemoradiation 49 ng mL 49 pre menopausal 49 mg d 49 plus methotrexate 49 COPAXONE R 49 leukopenia 49 HCV infected 49 nmol L 49 stent restenosis 49 mcg kg 49 seroconversion 49 Taxotere ® 49 % CI #.#-#.# [002] 49 plus prednisone 48 confidence interval CI 48 castration resistant prostate cancer 48 adjuvant therapy 48 #mg dose [003] 48 pioglitazone 48 knee OA 48 n = 48 cardiovascular mortality 48 prognostic factors 48 NRTI 48 mmol L 48 severe renal impairment

Back to home page